TAS0728 Inhibitor

MBS5758684 is an inhibitor targeting TAS0728. TAS0728 is a HER2 inhibitor, with antitumor activity

Irie H, Ito K, Fujioka Y,et al. TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models.Mol Cancer Ther. 2019 Apr ;18(4):733-742.
Irie H, Ito K, Fujioka Y,et al. TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models.Mol Cancer Ther. 2019 Apr ;18(4):733-742.
Ma F, Li Q, Chen S, et al. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer[J]. Journal of Clinical Oncology, 2017, 35(27):3105-3112.
Ma F, Li Q, Chen S, et al. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer[J]. Journal of Clinical Oncology, 2017, 35(27):3105-3112.

Small volumes of TAS0728, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.